GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Mangoceuticals Inc (NAS:MGRX) » Definitions » Net Income

MGRX (Mangoceuticals) Net Income : $-9.13 Mil (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mangoceuticals Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Mangoceuticals's Net Income for the three months ended in Jun. 2024 was $-2.39 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jun. 2024 was $-9.13 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Mangoceuticals's Earnings per Share (Diluted) for the three months ended in Jun. 2024 was $-0.09.


Mangoceuticals Net Income Historical Data

The historical data trend for Mangoceuticals's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mangoceuticals Net Income Chart

Mangoceuticals Annual Data
Trend Dec21 Dec22 Dec23
Net Income
- -2.00 -9.21

Mangoceuticals Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -2.28 -1.80 -2.57 -2.37 -2.39

Mangoceuticals Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Mangoceuticals's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-9.212+0+0+0
=-9.21

Mangoceuticals's Net Income for the quarter that ended in Jun. 2024 is calculated as

Net Income(Q: Jun. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-2.391+0+0+0
=-2.39

Net Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mangoceuticals  (NAS:MGRX) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Mangoceuticals's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Mangoceuticals Net Income Related Terms

Thank you for viewing the detailed overview of Mangoceuticals's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Mangoceuticals Business Description

Traded in Other Exchanges
N/A
Address
15110 N. Dallas Parkway, Suite 600, Dallas, TX, USA, 75248
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provide access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED product.
Executives
Amanda Elizabeth Hammer officer: Chief Operating Officer 5128 GADSDEN AVENUE, KELLER TX 76244
Jacob D. Cohen director, 10 percent owner, officer: CEO 2101 GLENDALE DRIVE, PLANO TX 75023
Tiger Cub Trust 10 percent owner 19 RYDDINGTON PL, DALLAS TX 75230
Kenny Myers director 5101 ADDISON CIRCLE,, UNIT 401,, ADDISON TX 75001
Lorraine Pamela D'alessio director 8200 WILSHIRE BLVD, BEVERLY HILLS, CALIFORNIA CA 90211
Eugene M Johnston officer: CFO PO BOX 669047, CHARLOTTE NC 28266
Jonathan Arango director, officer: President, COO and Secretary 15110 DALLAS PARKWAY, SUITE 600, DALLAS TX 75248
Alex P. Hamilton director 26 LOOP ROAD, BEDFORD NY 10506